New Tuberculosis Treatment, Old Problems: 100% Adverse Reactions in Thai Tuberculosis Patients on the Rifapentine-Moxifloxacin Regimen
Abstract
Abstract Introduction: The 4-month rifapentine-moxifloxacin (HPMZ) regimen has recently been shown to be as effective as the standard 6-month rifampicin-based regimen for drug-susceptible pulmonary tuberculosis. Clinical trials reported serious adverse drug reactions (ADRs) in only 18% of patients, with a low incidence of grade 3 hyperbilirubinemia (3.3%) in the HPMZ group. However, real-world practice at our institute in Thailand has suggested otherwise. Case description: We report a case series of four patients with pulmonary tuberculosis treated with the HPMZ regimen at the Central Chest Institute of Thailand in 2023. All four patients developed serious ADRs within the first 21 days of starting the regimen: Case 1: A 58-year-old woman started on HPMZ. After 12 days, she reported mild fatigue and nausea, with liver tests showing total bilirubin (TBIL)/direct bilirubin (DBIL) of 4.2/3.04 mg/dL, indicating grade 3 cholestasis from rifapentine. Case 2: A 65-year-old man started on HPMZ. After 15 days, while being asymptomatic, liver tests showed TBIL/DBIL levels of 4.3/3.19 mg/dL. He was diagnosed with grade 3 cholestasis due to rifapentine. Case 3: A 72-year-old male with COPD and paroxysmal atrial fibrillation started on HPMZ. His TBIL/DBIL were initially 1.1/0.45 but rose to 3.7/2.57 mg/dL after 21 days indicating grade 3 cholestasis attributed to rifapentine. He also experienced severe myalgia, arthralgia, and hypoglycemia from Moxifloxacin. Case 4: 73-year-old male…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.